SOURCE: ChromoCure, Inc.

December 16, 2009 10:40 ET

ChromoCure, Inc. to Open New Diagnostic and Research Center

RENO, NV--(Marketwire - December 16, 2009) - ChromoCure, Inc. (PINKSHEETS: KKUR) announced today its new Southeast Research Center to be based in Aventura, Florida.

The newly planned center is intended as a geographical central hub for direct partnership with cancer diagnostic laboratories and other cancer research centers. The new center will be in addition to the company's operations based in New York.

The new center will be open to pathologists and cancer researchers who wish to tour or utilize the Company's technology.

The company's systems and technology detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company's technology also objectively measures, with high precision, the level of cancer present and its stage of progression.

The center will receive a ChromoCure CS200 Chromosomal Scanner and will offer equipment training, theoretical education, and lab support to research and pathology partners.

The center's anticipated opening is during the first quarter of 2010. The launch of this facility is part of the Company's planned geographic expansion as well as providing a base for the Company's upcoming research initiatives to be announced ahead of the opening.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information